55. Goetz R, Nakada Y, Hu M et al. Abstract Background. High fibroblast growth factor-23 (FGF-23) levels are associated with adverse outcomes. We studied the responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD) and healthy control patients. Methods. Thirty patients were enrolled: 18 normophosphatemic CKD subjects and 12 healthy controls. The study duration was 21 days with three 7-day dietary interventions; a high phosphate (HP, 2000 mg/day), low phosphate (750 mg/day) and low phosphate plus phosphate binder (aluminum hydroxide, 500 mg thrice daily with meals), with comparable macronutrient content, administered in random sequence. Baseline and weekly fasting morning measurements of FGF-23, serum phosphate (sPO 4 ), 1,25-hydroxyvitamin D (1,25 D) and 24-h urinary calcium (uCa) and phosphate (uPO 4 ) were collected. Results. FGF-23 levels were higher in subjects versus controls (72 pg/mL versus 30 pg/mL) at baseline, while sPO 4 remained in the normal range throughout the study. The absolute changes of uPO 4 and uCa for CKD and controls vary according to diet. The absolute changes of FGF-23 and sPO 4 suggest that the effect of the diets might also depend on the CKD status (P-values interaction effect = 0.08 and 0.07, respectively); nonetheless, these changes are evident as a function of dietary interventions, irrespective of CKD status (P-values diet effect = 0.006 and <0.001, respectively). Conclusions. FGF-23 levels appear to be responsive to changes in diet in both CKD patients and controls. Further studies are required to determine whether lowering dietary phosphate and thus FGF-23 levels are of long-term benefit in CKD patients, irrespective of sPO 4 levels.
Abstract
Background. High fibroblast growth factor-23 (FGF-23) levels are associated with adverse outcomes. We studied the responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD) and healthy control patients. Methods. Thirty patients were enrolled: 18 normophosphatemic CKD subjects and 12 healthy controls. The study duration was 21 days with three 7-day dietary interventions; a high phosphate (HP, 2000 mg/day), low phosphate (750 mg/day) and low phosphate plus phosphate binder (aluminum hydroxide, 500 mg thrice daily with meals), with comparable macronutrient content, administered in random sequence. Baseline and weekly fasting morning measurements of FGF-23, serum phosphate (sPO 4 ), 1,25-hydroxyvitamin D (1,25 D) and 24-h urinary calcium (uCa) and phosphate (uPO 4 ) were collected. Results. FGF-23 levels were higher in subjects versus controls (72 pg/mL versus 30 pg/mL) at baseline, while sPO 4 remained in the normal range throughout the study. The absolute changes of uPO 4 and uCa for CKD and controls vary according to diet. The absolute changes of FGF-23 and sPO 4 suggest that the effect of the diets might also depend on the CKD status (P-values interaction effect = 0.08 and 0.07, respectively); nonetheless, these changes are evident as a function of dietary interventions, irrespective of CKD status (P-values diet effect = 0.006 and <0.001, respectively). Conclusions. FGF-23 levels appear to be responsive to changes in diet in both CKD patients and controls.
Introduction
The human protein fibroblast growth factor-23 (FGF-23) is phosphatonin, which influences the activity of sodiumphosphate co-transporters in the proximal tubule (and possibly the gastrointestinal tract), decreasing phosphate reabsorption and increasing phosphate excretion [1] . High FGF-23 levels are associated with death and cardiovascular events in subjects with chronic kidney disease (CKD) even before the initiation of dialysis [2, 3] . In addition, dysregulation of mineral metabolism and the secondary hyperparathyroidism (SHPT) are associated with increased cardiovascular risk [4] . SHPT develops in part to maintain normal or near-normal levels of serum phosphate (sPO 4 ) and calcium (sCa), but the exact level of estimated glomerular filtration rate (eGFR) at which this process begins is currently unknown. Previous studies [5, 6] have described the changes of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D (1,25D) at eGFR levels as high as 40-50 mL/min; whereas sPO 4 levels are maintained within the normal range. FGF-23 decreases the production of 1,25D by both the suppression of 1-α-hydroxylase and the induction of 24-hydroxolase. FGF-23 receptors are thought to initiate downstream signaling events along with Klotho, which acts as a cofactor. Murine models with inactivation of either FGF-23 or Klotho demonstrate oxidative stress, apoptosis, tissue atrophy, vascular calcification, premature aging and early death [7] .
The response of FGF-23 to diet has been described in healthy individuals [8] [9] [10] [11] . In CKD patients, Isakova et al. described the response of circulating FGF-23 to 14-day phosphate alterations by diet and binders but did not demonstrate significant reduction [12] , while recent studies by Moe et al. showed a lower FGF-23 when dietary protein comes from a vegetarian diet compared with a meat diet [13] . Historically, dietary phosphate restriction has been demonstrated to prevent the development of SHPT in both animals and humans [14] [15] [16] . Further experimental studies in animals postulated that a dietary restriction of phosphate (± protein) could slow the progression of CKD, though the mechanisms were not fully understood at that time [17] . The Modification of Diet in Renal Disease (MDRD) study (dietary protein plus phosphate restriction) was unable to demonstrate a significant slowing of the progression of CKD in humans [18] . Nonetheless, with increasing understanding of the link between FGF-23, phosphate and progression, and the finding that high levels of FGF-23 are associated with adverse outcomes, it is of interest to better understand the impact of high, low and very low phosphate intake on FGF-23 levels in CKD patients who have sPO 4 within the normal range (0.8-1.6 mmol/L).
Using a physiological experimental approach, this study aims to investigate the response to increased and decreased dietary phosphate intake on the following outcome variables; circulating FGF-23, in addition to sPO 4 , 1,25D, 24-h urinary calcium (uCa) and phosphate (uPO 4 ) excretion, in both CKD patients and healthy controls, who have maintained a normal sPO 4 level. We hypothesized that FGF-23 and the other biomarkers are responsive to changes in dietary phosphate intake, and their response would be similar in the two groups.
Subjects
A total of 32 subjects were recruited from October 2008 to February 2010 at St Paul's Hospital in Vancouver, British Columbia. Ethical approval was granted in May 2008 by the Providence Health Care and University of British Columbia institutional review board. All studied subjects provided written informed consent, were ≥19 years of age, had normal and stable sPO 4 over 3 months (0.87-1.70 mmol/L) and were not following a low phosphate (LP) diet (<1000 mg/day) as reported by the subject or their dietitian. Subjects were included with a eGFR (MDRD) of 15-60 mL/min for CKD subjects and eGFR > 90 mL/min with normal urine albumin-to-creatinine ratio for controls, and excluded if they were on phosphate binders, 1-α-calcidol, calcitriol or phenytonin, had a body mass index of <20 kg/m 2 , primary hyperparathyroidism, osteoporosis, gut absorption defects, liver disease, pregnancy, lactation or hospitalization within the last 4 weeks. No niacin or niacin-like compounds were used by any of the participants. Those who had been prescribed phosphate binders and were otherwise eligible (5/20 or 25%) were asked to stop their binder for 1 month prior to start of the study. Controls were recruited from kidney clinic staff.
Two of the CKD subjects attended the baseline visits but not subsequent visits; therefore, there are no followup data for these subjects. As a result, measurements of 30 subjects were analysed: 18 CKD subjects (16 stage 3 and only 2 stage 4) and 12 healthy controls. Two of the control subjects failed to complete blood and urine samples for either one or two of the diet periods, and therefore that specific data are missing.
Methods
The study randomized subjects to one of the three periods, in which one of the three diets was administered, and used a crossover design. The following diets/treatments were administered:
• High phosphate (HP) diet (2000 mg /day).
• Low phosphate (LP) diet (750 mg/day).
• Low phosphate plus phosphate binder diet (LP + B) (750 mg/day with the addition of aluminum hydroxide; 500 mg thrice daily with meals).
Full nutritional analysis of the diets was undertaken using the comprehensive dietary analysis package Food Processor™, from esha RE-SEARCH, Salem, Oregon. The diets were designed such that while dietary phosphate was vastly different, there was a minimal variation in protein and energy. Table 1 describes the content of key components of each diet. Each of the diets was supervised and crafted by a trained dietician containing fresh fruits, vegetables, meat and dairy products to reflect subjects personal preferences (where flexible) to maximize compliance, all of which were catalogued using food records (see Supplementary data for menus). The variation in phosphate content of the foods came mainly from non-perishable manufactured food products, as these provided an ideal portion of the control and are known to contain extremely high and low phosphate contents. The actual phosphate content was calculated using Food Processor™ software (which utilizes US department of agriculture analysis data). On entry to the study, subjects completed a food diary to ensure a moderate phosphate intake at baseline (1250-1750 mg/day). All subjects were randomly assigned to 1/6 sequences (see Table 2 ), and stayed under the corresponding three diets for a period of 7 days each.
Assessment of compliance with diet
We took a three pronged approach to compliance; (i) where possible, food stuffs and weighing scales were provided to allow subjects to measure weights of protein-containing foods, and weighed out portions were provided where possible (e.g. breakfast cereal was provided in individual bags), (ii) intensive counseling and time were devoted to ensure people understood the dietary intervention, (iii) individuals kept a diary of their dietary intake during the study, highlighting any deviations from the recommendations. These diaries were assessed at the end of each week, and compliance was found to be excellent.
Measurements
Morning fasting blood samples and a 24-h urinary collection were taken at baseline and at the end of each week. UCa and uPO 4 were analysed locally using standard autoanalyser techniques. iPTH was assessed using the Immulite 2500 (Siemens). Serum samples were stored at -80°C and analysed in batch for intact FGF-23, sPO 4, 25-dihydroxyvitamin D (25D) and 1,25D. 25D was analysed using liquid chromatography tandem mass spectrometry (API5000, Applied Biosystems). 1,25D was analysed using the 1,25D EIA kit (Immunodiagnostic Systems, UK) with a detection range of 6-500 pmol/L. Serum intact FGF-23 was assessed in duplicate using the Kainos (Japan) ELISA, with a detection limit of 3-800 pg/mL and intra-and inter-assay coefficient of variation 3.0-2.0% and 3.8-2.1%.
Statistical analysis
Descriptive statistics at baseline are presented as median (Interquartile Range, IQR) for continuous variables. Categorical variables are displayed as percentages. An unpaired t-test for normally distributed variables, two-sided exact Wilcoxon-Mann-Whitney for non-normally distributed variables and Fisher's exact test for categorical variables are used to assess between-group variables at baseline. Normality of the outcome variables is assessed using the Shapiro-Wilk test at a significance level of 0.05. Associations with FGF-23 and other biochemical markers are undertaken using Spearman's correlation coefficient. Boxplots are used to display the distributions of the percentage change with respect to the baseline of the five biochemical markers for CKD and healthy control groups and the three phosphate diets. Descriptive statistics of the absolute change from baseline for each biochemical markers are presented as median (IQR) by type of diets and by CKD status.
The study is based on a crossover design, which reduces the betweensubjects variability from the three phosphate diets. However, measurements within subjects are correlated due to the fact that several measurements are made on each subject. Consequently, a mixed-effect modeling technique is used to account for the correlated data when investigating the impact of the different dietary interventions on the absolute change from baseline in each biochemical marker. For the model set-up, the dependent variable is the absolute change from baseline. Subjects are declared as the random effect. Furthermore, we account for the potential presence of carryover effects controlling for the different sequences of diets (Table 2 ). Additional independent variables considered in the model are diet, CKD status, period, previous diet, biomarker measurement at the end of the previous diet, biomarker measurement at baseline, age as well as an interaction term between phosphate diet and CKD status. In the event that the interaction term between phosphate diet and CKD status is not statistically significant, the model is refitted excluding the interaction term, and in that case the main effects on phosphate diet and CKD status are also reported; otherwise, only the significance of the interaction term is reported. Computation of the mixed model was performed in SAS software, version 9.2 (SAS Institute, Cary, NC).
Results

Cohort baseline characteristics
A description of the study cohort is shown in Table 3 . Other than age, the CKD and healthy control groups were similar with respect to clinical parameters: the CKD group is significantly older (68 versus 40 years, P < 0.001). While the sPO 4 , sCa and albumin were not statistically significantly different between the two groups, the CKD group had significantly higher FGF-23, 25D and iPTH and lower 1,25D levels. At baseline, for the whole study cohort, FGF-23 correlated positively with iPTH (r = 0.45, P = 0.01) and 25D (r = 0.45, P = 0.02), and negatively with eGFR (r = −0.74, P < 0.001), 1,25D (r = −0.70, P < 0.001), 24-h uCa excretion (r = −0.60, P < 0.001) and albumin (r = −0.49, P = 0.005). In addition, 1,25D correlated positively with eGFR (r = 0.63, P < 0.001) and albumin (r = 0.39, P = 0.03). SPO 4 correlated negatively with 25D (r = −0.39, P = 0.04), and 24-h uCa excretion is positively correlated with eGFR (r = 0.62, P < 0.001) and negatively with iPTH (r = −0.43, P = 0.02). UPO 4 excretion is not significantly correlated with any measure. SCa and iPTH correlated positively with albumin (r = 0.66, P < 0.001) and 24-h urine protein (r = 0.37, P = 0.05), respectively. Since some baseline values are statistically significantly different between CKD and control groups, correlations within the CKD group were also calculated. In this case, only FGF-23 is negatively correlated with 1,25D (r = −0.49, P = 0.04) 
High phosphate (HP) diet, low phosphate (LP) diet, low phosphate plus phosphate binder (LP + B) diet.
Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intakeand albumin (r = −0.58, P = 0.01), and sCa is positively correlated with albumin (r = 0.70, P = 0.001).
Descriptive analysis: diet and biochemical markers Table 4a describes the crude measurement of the biochemical markers (median with IQR) at baseline and at the end of each diet, by type of diet intake and by CKD status. SPO 4 remains in the normal range for the duration of the study. FGF-23 levels are higher in CKD than in controls at baseline (72 pg/mL versus 30 pg/mL) and throughout the study. iPTH and sCa appear to be similar between CKD subjects and healthy controls during the study. Table 4b presents a descriptive summary (median with IQR) of the absolute change from the baseline for each biochemical marker by type of diet intake and by CKD status. Similarly, Figure 1 presents boxplots of the percentage change of the five biochemical markers according to the three phosphate intake diets, in both groups.
This descriptive analysis suggests that the absolute change and percentage change in FGF-23, sPO 4 , uPO 4 , and uCa appears to vary among the different phosphate diets; within each of these biomarkers, the response of the absolute and percentage change to different phosphate diets seems to have a similar direction between CKD and healthy controls. This analysis also suggests that the magnitude of the absolute change in FGF-23 might be larger in the CKD group than in the controls when a LP diet is introduced, irrespective of the baseline phosphate or previous diet. Similarly, for the biomarkers uPO 4 and uCa, the magnitude of the absolute change might potentially differ between CKD and control groups at a given type of diet intake. For the case of sPO 4 , the data suggest that the absolute change from baseline is similar between both groups.
There appears to be no difference in the absolute and percentage change in iPTH and sCa. However, there does appear to be a difference in the absolute and percentage change of 1,25D among the different phosphate diets. Nevertheless, contrary to the other biomarkers, there appears to be a difference in the direction of the response between CKD and control subjects in response to different phosphate diets. The difference is presented in the LP diet, where there seems to be an increase in the median percentage change in 1,25D for the CKD subjects, while there seems to be a decrease for the control subjects. Table 4a and b and Figure 1 are provided for descriptive purposes to understand the absolute and percentage change of the biomarkers with respect to the baseline values. Appropriate P-values used to draw interpretation of the statistically significant effect associated with the exposure of diet and CKD status are based on mixedeffect models to include statistical adjustments and are reported in Table 5 . Table 5 depicts the results of the effect of phosphate diet, as well as CKD status, on the five biochemical markers from several mixed-effect models. For biomarkers iPTH and sCa, the results are not statistically significant (P > 0.1).
Mixed-effect model
The interactions between phosphate dietary intake and the CKD status on the absolute change from baseline in uPO 4 and uCa are statistically significant (P = 0.01 and 0.002, respectively). In other words, the absolute changes in uPO 4 and uCa for CKD and control subjects vary according to the phosphate dietary intake. Or, similarly, the effect of the phosphate dietary intake on the absolute changes in uPO 4 and uCa depends on the CKD status.
For the case of the absolute changes of FGF-23 and sPO 4 , the results suggest that the effect of the phosphate dietary intake might also depend on the CKD status Finally, there is no statistically significant evidence for an interaction effect between the phosphate dietary intake and the CKD status on the absolute change in 1,25D (Pvalue interaction effect = 0.94). In other words, phosphate diets and CKD status are independently associated with the absolute change in 1,25D from baseline (P-values <0.001 and 0.02, respectively).
Discussion
To our knowledge, this is the first and largest study to demonstrate that FGF-23, sPO 4 and 1,25D are responsive to changes in dietary phosphate in a contemporary cohort of both healthy controls and CKD patients, all of whom have sPO 4 within the normal range. Other studies have shown results on healthy adults, or on children with CKD, or adults with CKD with abnormal sPO4 values. The study tested the hypothesis that FGF-23 response is similar in control and CKD populations, who have normal sPO 4 levels. Using different diets we were able to demonstrate that FGF-23 is indeed responsive to changes in phosphate diets, all other major constituents of the diets being held constant, with the direction of change similar between controls and those with impaired kidney function. The data suggest that in the CKD population, the magnitude of the change in FGF-23 is different when a very LP diet is introduced, irrespective of baseline phosphate or previous diet. This has previously not been demonstrated, and is intriguing in light of the fact that dietary restriction of phosphate has been shown to reduce progression of CKD. Inasmuch as FGF-23 may be contributing to progressive kidney decline, this finding warrants further study.
The direction of the impact of diet on FGF-23 values is the same across the two cohorts, with some suggestion that the magnitude of change is different in CKD patients on a very LP diet. As described in Table 5 , there is statistical evidence that the absolute change of FGF-23 is highly responsive to the phosphate dietary intake (P-value diet effect = 0.006). The results suggest that the effect of the phosphate dietary intake on the absolute change of FGF-23 might also depend on the CKD status (P-value interaction effect = 0.08).
Multiple dietary phosphate intervention studies investigating FGF-23 have been conducted in healthy populations [8, 9, 11, 19, 20] . Burnett et al. showed that FGF-23 is responsive to alterations in dietary phosphate, but the maximal response plateau at day 7, hence the chosen intervention period for the present study. Consistent with this finding, studies in CKD populations who had a dietary phosphate intervention for <7 days were unable to demonstrate changes in circulating levels of FGF-23 [9, 20] . Surprisingly, Isakova et al. had a two-week dietary intervention period, but were unable to demonstrate changes in serum FGF-23 levels despite significant alterations in uPO 4 levels [12] . The authors have proposed that this finding is due to the short intervention time; however, other explanations may be plausible. Our findings are consistent with the majority of previous studies showing that small changes in sPO 4 , in response to alterations in dietary phosphate, do alter FGF-23, but these changes are variable [8, 9, 11, 19, 20] .
As in all studies there are limitations: First, there was a lack of washout period between the intervention periods. This was due to pragmatic reasons which included the need to ensure that the study could be completed by each individual within a 4-week period, as adherence, commitment and clinical stability were deemed essential for this study. We chose instead to allocate the sequences randomly, and thus take advantage of different 'prior' exposures to phosphate. The prior diet and the random sequence have been accounted for within the statistical analysis and thus this is a relative limitation. Irrespectively, we would point out that the expected response in the biomarkers was observed. The lack of washout period would have served to bias the results to the conservative, thus we believe this to be a relative limitation. Additional limitations of the study include its small sample size and timing of blood work. Studies that entail intense counseling, dietary review and measurements are by necessity resource intense, which leads to a small sample size. We attempted to maximize the information from each patient by exposing them to all diets, in random order as described above. We did use fasting morning blood work, and some would argue that use of morning blood work is problematic for ascertaining differences in sPO 4 (because the values are known to fluctuate dramatically throughout the day) [21] . However, given that our goal was to practically evaluate the impact of different diets on FGF-23, not on sPO 4 , we do not think that this timing issue is a major limitation. Furthermore, in clinical practice, morning or fasting blood work is the norm, so that decision making based on those values is clinically relevant. We did not Other covariates included in the model: diet sequence, period, previous diet, biomarker measurement at the end of the previous diet, biomarker measurement at baseline and age; in addition to subject as a random effect.
directly measure the phosphate content, and instead estimated the content of phosphate diet based on the nonperishable goods documentation. We did not have access to apparatus to measure the phosphate content, but have used this clinically 'translatable' measure of phosphate (content as described on packaging), which is used in advice given by dieticians. Thus, this study design and methodology could be viewed as very translatable to clinical practice. An additional limitation in this study exploring FGF-23 responsiveness is the lack of data on (soluble) Klotho [22, 23] . Given that CKD is thought to be a state of Klotho deficiency, this information would have been useful for further interpretation. Unfortunately, we are not able to measure sKlotho.
The results from this study suggest that a LP diet could have beneficial effects on FGF-23 for CKD patients as early as stage 3, but the level of dietary restriction used herein may not be suitable as a long-term target for CKD subjects, as it is overly restrictive, bland and may lead to nutrient deficiencies. If intentions to introduce this degree of phosphate restriction were applied clinically, and if the attenuation of FGF-23 levels was shown to be beneficial, more palatable diets would need to be devised. The addition of the phosphate binder does permit some flexibility in the dietary intake.
Dietary phosphate restriction is not the same as protein restriction, and severe protein restriction has been associated with harm in CKD patients [24] . Although many foods which are high in phosphate also contain high levels of protein, these are not always concordant as shown by Moe et al [13] . It is possible to achieve low phosphate, moderate protein intake given the heavy reliance on processed foods available across the globe [25] . However, it remains to be proven that lower FGF-23 levels are of benefit in the long term. Further studies are required to demonstrate that maintenance of lower FGF-23 levels with nutritionally sufficient LP diets is beneficial.
This study confirms the findings of others [8, 12, 13, 26] and extends them, leading to new research directions. Unanswered questions such as what levels of FGF-23 are 'adaptive' versus 'maladaptive', when and if FGF-23 loses its responsive to diet in patients with CKD, and whether alterations in FGF-23 values that are sustained lead to long-term benefits, which need to be answered in future studies.
Raised FGF-23 has been repeatedly demonstrated in dialysis patients and more recently in pre-dialysis CKD populations [2, 27] ; to be associated with adverse outcomes. It is extremely important that it is possible to manipulate FGF-23 levels using an LP diet and lowered further using a binder. Further studies are required to understand the importance of absolute values, versus relative changes in FGF-23 levels within CKD populations, the impact and range of change that can be induced with various manipulations and which manipulations can be successfully implemented in clinical practice. This study, in combination with other experimental and clinical studies, should form the basis of ongoing investigation into the complex relationship between FGF-23, sPO 4 , 1,25D, uPO 4 and uCa in the progression of CKD and cardiovascular disease.
We believe that this study provides important information about FGF-23 in CKD populations with normal sPO 4 levels, and demonstrates the impact of dietary manipulation of phosphate intake on these parameters.
